Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition

Leukemia Research

Volumn 39, Issue 9, 2015, Pages 984-989

  Drusbosky, Leylah ^a   Gars, Eric ^a   Trujillo, Angelica ^a   McGee, Christie ^a   Meacham, Amy ^a   Wise, Elizabeth ^a   Scott, Edward W ^b   Cogle, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN A; ANTINEOPLASTIC ANTIMETABOLITE; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR AB; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BONE MARROW ENDOTHELIAL CELL; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CELL PROTECTION; CELL VIABILITY; CELLULAR SECRETION; COCULTURE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SCID MOUSE; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTARABINE; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84940930249     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.05.015     Document Type: Article

References (37)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. New Engl. J. Med. 1999, 341(14):1051-1062.
2. Appelbaum F.R., et al. Age and acute myeloid leukemia. Blood 2006, 107(9):3481-3485.
3. Chauncey T.R., et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br. J. Haematol. 2010, 148(1):48-58.
4. Roboz G.J., et al. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leuk. Lymphoma 2015, 56(2):395-400.
5. Morrison S.J., Scadden D.T. The bone marrow niche for haematopoietic stem cells. Nature 2014, 505(7483):327-334.
6. Butler J.M., et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010, 6(3):251-264.
7. Kobayashi H., et al. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nat. Cell Biol. 2010, 12(11):1046-1056.
8. Poulos M.G., et al. Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep. 2013, 4(5):1022-1034.
9. Grant M.B., et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat. Med. 2002, 8(6):607-612.
10. Cogle C.R., et al. Adult human hematopoietic cells provide functional hemangioblast activity. Blood 2004, 103(1):133-135.
11. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95(1):309-313.
12. Padro T., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000, 95(8):2637-2644.
13. Loges S., et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J. Clin. Oncol. 2005, 23(6):1109-1117.
14. Lee C.Y., et al. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br. J. Cancer 2007, 97(7):877-882.
15. Shih T.T., et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009, 113(14):3161-3167.
16. Cogle C.R., et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia 2014, 28(10):1978-1987.
17. Pezeshkian B., et al. Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism. PLOS ONE 2013, 8(4):pe60823.
18. Poulos M.G., et al. Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. Exp. Hematol. 2014, 42(11):976-986. e1-3.
19. Li H., et al. Pazopanib, a receptor tyrosine kinase inhibitor, suppresses tumor growth through angiogenesis in dedifferentiated liposarcoma xenograft models. Transl. Oncol. 2014, 7(6):665-671.
20. Hansen R.N., et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J. Manag. Care Spec. Pharm. 2015, 21(1):37-44. 44a-d.
21. Delea T.E., et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J. Manag. Care Spec. Pharm. 2015, 21(1):46-54. 54a-b.
22. Chervontseva A.M., Romanov Iu A., Savchenko V.G. [Effect of cytarabine on expression of cell adhesion molecules and on endothelium-leukocyte interaction in vitro]. Ter. Arkh. 2006, 78(7):67-72.
23. Romanov Y.A., et al. Vascular endothelium: target or victim of cytostatic therapy?. Can. J. Physiol. Pharmacol. 2007, 85(3-4):396-403.
24. Liersch R., et al. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk. Res. 2008, 32(6):954-961.
25. Dias S., et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(19):10857-10862.
26. Walter M.J., et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 2012, 366(12):1090-1098.
27. Welch J.S., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150(2):264-278.
28. Hatfield K., et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br. J. Haematol. 2009, 144(1):53-68.
29. Padro T., et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002, 16(7):1302-1310.
30. Fiedler W., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89(6):1870-1875.
31. Karp J.E., et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin. Cancer Res. 2004, 10(11):3577-3585.
32. Zahiragic L., et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007.
33. Fiedler W., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105(3):986-993.
34. Fiedler W., et al. An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk. Res. 2010, 34(2):196-202.
35. Fiedler W., et al. A phase I/II study combining sunitinib with standard ara-C/daunorubicin chemotherapy in patients 60 years or older with FLT3 mutated AML. ASH Ann. Meet. Abstr. 2010, 116(21):3285-.
36. Dias S., et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99(6):2179-2184.
37. Wunderlich M., et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 2013, 121(12):e90-e97.